NCT00910455

Study of SRX246 Capsules in Healthy Adult Volunteers

Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Azevan Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.

Detailed description

This protocol represents the first in human study of SRX246, and is being conducted to begin to establish a safety profile, and collect human tolerability and pharmacokinetic data of orally administered SRX246.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	SRX246	single oral dose of SRX246 capsule
DRUG	Placebo	Single oral dose of placebo capsule

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2009-05-29
• Last updated: 2010-03-17

Locations

1 site across 1 country: United States